TrialBlood2015

Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis.

Rami S Komrokji et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.